1. National Institute of Mental Health, USA
2. University of Cambridge, UK
3. University of Edinburgh, UK

Abstract

The bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of cholesterol. Selective agonists are promising drugs for the treatment of metabolic disorders, such as type II diabetes, obesity and atherosclerosis.

Contents

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [2].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

References

1. Baxter JD and Webb P. (2006) Metabolism: bile acids heat things up. Nature 439: 402-403 [PMID:16437098]
2. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it Database 2020 [PMID:32367113]
3. de Oliveira MC, Gilglioni EH, de Boer BA, Runge JH, de Waart DR, Salgueiro CL, Ishii-Iwamoto EL, Oude Elferink RP and Gaemers IC. (2016) Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice. Biochim Biophys Acta 1862: 2054-2062 [PMID:27475255]
4. Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, Vimal M, Szewczyk GR, Jayawickreme C and Moncol DL et al.. (2009) Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem 52: 7962-5 [PMID:19902954]
5. Fiorucci S, Cipriani S, Baldelli F and Mencarelli A. (2010) Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 49: 171-85 [PMID:19932133]
6. Fiorucci S, Mencarelli A, Palladino G and Cipriani S. (2009) Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 30: 570-80 [PMID:19758712]
7. Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, Schoonjans K, Souchet M, Auwerx J, Saladin R and Wagner A. (2010) Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 53: 178-90 [PMID:19911773]
8. Guo C, Chen WD and Wang YD. (2016) TGR5, Not Only a Metabolic Regulator. Front Physiol 7: 646 [PMID:28082913]
9. Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, Zheng M, Zhang X, Xia D and Ke Y et al.. (2016) Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. Immunity 45: 802-816 [PMID:27692610]
10. Houten SM, Watanabe M and Auwerx J. (2006) Endocrine functions of bile acids. EMBO J 25: 1419-25 [PMID:16541101]
11. Högenauer K, Arista L, Schmiedeberg N, Werner G, Jaksche H, Bouhelal R, Nguyen DG, Bhat BG, Raad L and Rauld C et al.. (2014) G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype. J Med Chem 57: 10343-54 [PMID:25411721]
12. Katsuma S, Hirasawa A and Tsujimoto G. (2005) Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329: 386-90 [PMID:15721318]
13. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y and Fujino M. (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278: 9435-9440 [PMID:12524422]
14. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, Häussinger D and Kubitz R. (2007) The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45: 695-704 [PMID:17326144]
15. Lefebvre P, Cariou B, Lien F, Kuipers F and Staels B. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89: 147-91 [PMID:19126757]
16. Li B, Yang N, Li C, Li C, Gao K, Xie X, Dong X, Yang J, Yang Q and Tong Z et al.. (2018) INT-777, a bile acid receptor agonist, extenuates pancreatic acinar cells necrosis in a mouse model of acute pancreatitis. Biochem Biophys Res Commun 503: 38-44 [PMID:29859191]
17. Li T and Chiang JY. (2012) Bile Acid signaling in liver metabolism and diseases. J Lipids 2012: 754067 [PMID:21991404]
18. Londregan AT, Piotrowski DW, Futatsugi K, Warmus JS, Boehm M, Carpino PA, Chin JE, Janssen AM, Roush NS and Buxton J et al.. (2013) Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries. Bioorg Med Chem Lett 23: 1407-11 [PMID:23337601]
19. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H and Tanaka K. (2002) Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298: 714-9 [PMID:12419312]
20. Pellicciari R, Gioiello A, Macchiarulo A, Thomas C, Rosatelli E, Natalini B, Sardella R, Pruzanski M, Roda A and Pastorini E et al.. (2009) Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 52: 7958-61 [PMID:20014870]
21. Pellicciari R, Sato H, Gioiello A, Costantino G, Macchiarulo A, Sadeghpour BM, Giorgi G, Schoonjans K and Auwerx J. (2007) Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J Med Chem 50: 4265-8 [PMID:17685603]
22. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L and Pellicciari R et al.. (2011) TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14: 747-57 [PMID:22152303]
23. Pols TW, Noriega LG, Nomura M, Auwerx J and Schoonjans K. (2011) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 54: 1263-72 [PMID:21145931]
24. Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX and Jiang T et al.. (2010) Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 78: 617-30 [PMID:20631053]
25. Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, Mioskowski C, Auwerx J and Saladin R. (2007) Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 362: 793-8 [PMID:17825251]
26. Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, Saladin R, Schoonjans K, Pellicciari R and Auwerx J. (2008) Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 51: 1831-41 [PMID:18307294]
27. Takada Y and Aggarwal BB. (2003) Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 171: 3278-86 [PMID:12960358]
28. Takeda S, Kadowaki S, Haga T, Takaesu H and Mitaku S. (2002) Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 520: 97-101 [PMID:12044878]
29. Thomas C, Auwerx J and Schoonjans K. (2008) Bile acids and the membrane bile acid receptor TGR5--connecting nutrition and metabolism. Thyroid 18: 167-74 [PMID:18279017]
30. Tiwari A and Maiti P. (2009) TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov Today 14: 523-30 [PMID:19429513]
31. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, Hoos L, Tetzloff G, Levitan D and Murgolo NJ et al.. (2006) Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J 398: 423-30 [PMID:16724960]
32. Wang XX, Edelstein MH, Gafter U, Qiu L, Luo Y, Dobrinskikh E, Lucia S, Adorini L, D'Agati VD and Levi J et al.. (2016) G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. J Am Soc Nephrol 27: 1362-78 [PMID:26424786]
33. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O and Kodama T et al.. (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-9 [PMID:16400329]
34. Yang JI, Yoon JH, Myung SJ, Gwak GY, Kim W, Chung GE, Lee SH, Lee SM, Kim CY and Lee HS. (2007) Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem Biophys Res Commun 361: 156-161 [PMID:17659258]
35. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H and Yoshiba M. (2007) Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 354: 154-9 [PMID:17214962]
36. Yun Y, Zhang C, Guo S, Liang X, Lan Y, Wang M, Zhuo N, Yin J, Liu H and Gu M et al.. (2021) Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5^H88Y Mutant Mice. J Med Chem [PMID:34406006]